Estimating Atherosclerosis Cardiovascular Disease Risk of 10-year with the Systemic Coronary Risk Estimation Method and Statin Use Recommendation

Nurmainah - Nurmainah, Syarifah N.Y.R.S Asseggaf

Abstract


Stroke and heart disease belong to atherosclerotic cardiovascular diseases (ASCVD), which is one of the death causes in Indonesia. This study aimed to estimate the risk of atherosclerosis cardiovascular disease in the next 10 years using the Systemic Coronary Risk Estimation (SCORE) method. This research was an observational study with descriptive cross-sectional study design. Respondent data collection was taken prospectively which means directs data was collected through interviews, blood pressure measurement, and peripheral blood sampling. The results showed that respondents who were involved in this study were those with an average age of 49.70 ± 7.1 years. Respondents were more dominated by women (76.1%); BMI of respondents showed in the non-obese group 27.14 ± 4.6 kg/m2; total cholesterol, LDL, TG, and HDL levels respectively had an average of 152.17 ± 39.5 mg/dL; 91.28 ± 40.9 mg/dL; 117.24 ± 96.9 mg/dL; and 30.87 ± 8.8. The number of respondents who smoke was 17.39% and that of those who have undergone physical activity in the form of sports was 60.87%. Based on the results of risk estimation using the SCORE method, it was found that the number of people who were in the low-risk category was 54.35% and the moderate risk category was 45.65%. This study concludes that the risk of ASCVD for the next 10 years in the community is at low and moderate levels. Non-pharmacological treatment is more recommended at this level and statins can be given to individuals if there is no improvement in cholesterol levels.


Keywords


Atherosclerosis Cardiovascular Siseases (ASCVD), SCORE, Statins

Full Text:

PDF

References


World Health Organization. Noncommunicable Diseases (NCD) Country Profiles. 2018.

Kementerian Kesehatan Republik Indonesia. Situasi Kesehatan Jantung. Jakarta: Pusat Data dan Informasi Kementerian Kesehatan Republik Indonesia; 2014.

Kesehatan BPJS. Lindungi Diri sejak Dini dari Penyakit Jantung [Internet]. 2017 [cited 2019 Mar 6]. Available from: https://bpjs-kesehatan.go.id/bpjs/index.php/post/read/2017/551/Lindungi-Diri-Sejak-Dini-dari-Penyakit-Jantung.

Badan Penelitian dan Pengembangan Kementerian Kesehatan Republik Indonesia. Hasil Riset Kesehatan Dasar (RISKESDAS) 2013. Jakarta: Kementerian Kesehatan Republik Indonesia; 2014. 258–260 p.

Garg N, Muduli SK, Kapoor A, Tewari S, Kumar S, Khanna R, et al. Comparison of different cardiovascular risk score calculators for cardiovascular risk prediction and guideline recommended statin uses. Indian Heart Journal. 2017;69(4):458–63.

Selvarajah S, Kaur G, Haniff J, Cheong KC, Hiong TG, Van Der Graaf Y, et al. Comparison of the Framingham Risk Score, SCORE and WHO/ISH cardiovascular risk prediction models in an Asian population. International Journal of Cardiology. 2014;176(1):211–8.

Erwinanto, Santoso A, Putranto J, Tedjasukmana P, Sukmawan R, Suyawan R. Panduan Tata Laksana Dislipidemia 2017. Jakarta: Perhimpunan Dokter Spesialis Kardiovaskular Indonesia; 2017. 1–49 p.

Park JE, Chiang CE, Munawar M, Pham GK, Sukonthasarn A, Aquino AR, et al. Lipid-lowering treatment in hypercholesterolaemic patients: The CEPHEUS Pan-Asian survey. European Journal of Preventive Cardiology. 2012;19(4):781–94.

Iskandar MF, Nurmainah N, Susanti R. The Risk of Atherosclerotic Cardiovascular Disease among Hyperlipidaemia Patients and Appropriateness of Statin Therapy. Pharmacology and Clinical Pharmacy Research. 2018;3(1).

Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the american college of cardiology/american heart association task force on practice guidelines. Circulation. 2014;129(25 SUPPL. 1):1–45.

Dwivani C, Harijadi K, Suhadi R. Perbandingan Lima Metode Estimasi Risiko 10 Tahun Penyakit Kardiovaskuler pada Masyarakat Kabupaten Sleman- Yogyakarta. Jurnal Manajemen dan Pelayanan Farmasi. 2018;8(2):59–69.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. European Heart Journal. 2020;41(1):111–88.

Liu ML, Reilly MP, Casasanto P, McKenzie SE, Williams KJ. Cholesterol enrichment of human monocyte/macrophages induces surface exposure of phosphatidylserine and the release of biologically-active tissue factor-positive microvesicles. Arteriosclerosis, Thrombosis, and Vascular Biology. 2007;27(2):430–5.

Sugiarti L, Latifah L. Hubungan Obesitas, Umur Dan Jenis Kelamin Terhadap Kadar Kolesterol Darah. Jurnal Kesehatan. 2017;1(1):84.

Ramos R, Comas-Cufí M, Martí-Lluch R, Balló E, Ponjoan A, Alves-Cabratosa L, et al. Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: Retrospective cohort study. British Medical Journal. 2018;362:1–4.

Brown F, Singer A, Katz A, Konrad G. Statin-prescribing trends for primary and secondary prevention of cardiovascular disease. Canadian Family Physician. 2017;63(11):e495–503.




DOI: https://doi.org/10.15416/pcpr.v5i3.26599

Refbacks

  • There are currently no refbacks.


                                                                         
Pharmacology and Clinical Pharmacy Research is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
 
                                                                      VIEW VISITOR STATS